Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 23-652
Assay Conditions: This protein was tested by ELISA. A 96-well plate was coated with HER2, Avi-His-Tag Recombinant overnight at 4°C (50 µl/well at a concentration of 100 ng/reaction in PBS). The next day the plate was washed 3 times with PBST and blocked using 200 µl of Blocking Buffer 3 (#79743) for 2 hours at Room Temperature (RT). After removing the blocking buffer, 50 µl/well of purified Anti-HER2, Sortase-His-tag Antibody (#101689), serially diluted in 1x PP-02 Buffer, was added for 1 hour at RT. After washing, the plate was incubated for 60 minutes with anti-Fc-HRP-labeled antibody 1:1000 in Blocking Buffer 3 (50 µl/well) and washed again. Finally, 100 µl of ECL substrate was added to each well and plate was read immediately in a luminometer or microtiter-plate reader capable of reading chemiluminescence.
Background: HER2 (human epidermal growth factor receptor 2), also known as erbB-2 or CD340, is a tyrosine kinase transmembrane receptor of the EFGR family of proteins. There is no known ligand, but it can form homodimers or heterodimers with other HER proteins. Once active, it activates the MAPK (mitogen-activated protein kinase) and PI3K (phosphatidylinositol-3 kinase) signaling pathways resulting in cell cycle progression and cell proliferation. HER2 overexpression is known to occur in breast, ovarian, stomach, lung adenocarcinoma, aggressive forms of uterine cancer, and gastric cancer. In 1990 the FDA approved the use of the monoclonal antibody trastuzumab (Herceptin) in breast and stomach cancer. Other approved strategies to target HER2 include ADCs (antibody-drug conjugate) and margetuximab (anti-HER2 antibody that can induce cytotoxicity). The development of treatments targeting early-stage cancer, with minimal side effects and resistance development, will bring major benefits to HER2-positive oncology patients.
Concentration: 0.14 mg/ml
Description: Recombinant human HER2 (human epidermal growth factor receptor 2, also known as ErbB2), encompassing amino acids 23-652 corresponding to the extracellular domain. This construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). This protein was affinity purified. This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Format: Aqueous buffer solution
Formulation: 8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Genbank: NM_004448.4
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 6 months at -80°C.
Tags: C-terminal Avi-His-tag
Uniprot: P04626
Warnings: Avoid multiple freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
English
Deutsch
